SCHEMBL5640329

SCHEMBL5640329

O=[C]N[C@H]1CCCCN(C(=O)Nc2ccccc2)C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.46
▸ NPC1 O15118 5/20 0.46
▸ RAB9A P51151 5/20 0.46
▸ TP53 P04637 4/20 0.46
▸ NFKB1 P19838 2/20 0.42
▸ NFKB2 Q00653 2/20 0.42
▸ RELA Q04206 2/20 0.42
▸ PKM P14618 1/20 0.42
▸ TSHR P16473 2/20 0.42
▸ NAMPT P43490 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MAPT P10636 3/20 0.40
▸ GAA P10253 2/20 0.40
▸ FAAH O00519 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ HTR1E P28566 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5637034 0.88 KMT2A (0.49) SMN1; SMN2NPC1RAB9ANAMPTKDM4E
SCHEMBL5638857 0.88 NPC1 (0.49) SMN1; SMN2NPC1RAB9ATP53NFKB1
SCHEMBL5638348 0.86 NPC1 (0.49) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL5637813 0.85 RAB9A (0.48) SMN1; SMN2NPC1RAB9ATP53NFKB1
SCHEMBL5638422 0.83 KMT2A (0.43) SMN1; SMN2NPC1RAB9ATP53TSHR
SCHEMBL5640334 0.82 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ATP53NFKB1
SCHEMBL5637461 0.82 ALDH1A1 (0.61) SMN1; SMN2TP53TSHRKDM4EALDH1A1
SCHEMBL5639158 0.81 ALDH1A1 (0.43) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL5638116 0.79 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9ATP53NFKB1
SCHEMBL5637053 0.79 ALDH1A1 (0.48) KDM4EALDH1A1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 — — US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 — — EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 — — US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 SMN1; SMN2 4121/4885NPC1 449/4885RAB9A 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback